Copyright
©The Author(s) 2022.
World J Clin Oncol. May 24, 2022; 13(5): 323-338
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.323
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.323
Figure 4 The repertoire of targeted cancers and therapeutic application of HN-1 peptide.
A: HN-1 uptake profile. The internalization of HN-1 peptide by various human cancer cells vs the corresponding normal human cells was compared. HN-1 uptake: red arrow (internalized), blue arrow (undetectable); B: Previously developed HN-1 based conjugates for therapy or diagnosis. Note: whether HN-17 peptide (consisting of a permutated version of HN-1 sequence) enters cells via the same route as HN-1 peptide or through a distinct route is not known. HOK: Human oral keratinocyte; NOE: Normal oral epithelial; NHDF: Normal human dermal fibroblasts; Cu: Copper; Tc: Technetium; PKCe: Protein kinase C epsilon; siRNA: Small interfering RNA; PEG: Polyethylene glycol.
- Citation: Hong FU, Castro M, Linse K. Tumor specifically internalizing peptide ‘HN-1’: Targeting the putative receptor retinoblastoma-regulated discoidin domain receptor 1 involved in metastasis. World J Clin Oncol 2022; 13(5): 323-338
- URL: https://www.wjgnet.com/2218-4333/full/v13/i5/323.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i5.323